Abstract 49P
Background
To date, miR-155 is known as an oncogenic miRNA with a well-documented role in breast cancer. Cancer stemness plays an important role in various aspects of carcinogenesis. The aim of this study is to investigate the effect of miR-155 on breast cancer proliferation by upregulating cancer stem cells.
Methods
In vivo-tumor growth and metastasis were measured across polyomavirus middle T antigen (PyVmT) transgenic mice and PyVmT miR-155 knockout mice. Western blot and quantitative real-time polymerase chain reaction (qRT-PCR) were employed to determine the protein and mRNA levels, respectively. The cancer stemness was assessed by sphere formation as well as the expression of the related markers. The miR-155 target genes were predicted and analyzed by western blot and luciferase assay.
Results
Upregulation of miR-155 in breast cancer tissues of mice identified poor prognosis and cancer metastasis. Upregulation of miR-155 was also found in breast cancer stem cells. Ectopic expression of miR-155 promotes the stemness of breast cancer cells. Conversely, depletion of miR-155 attenuates the stemness of these cells. miR-155 directly binds to CYLD and Sharp-1 to influence breast cancer stemness.
Conclusions
MicroRNA-155 promotes breast cancer progression by upregulating breast cancer stemness.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
30P - Role of microRNA and CDKN2A/p16INK4a expression in the prognostication of oral squamous cell carcinoma
Presenter: Olha Burtyn
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Identification of proteins associated with mRNA processing and maturation by quantitative proteomic analysis in Indian cervical cancer patients
Presenter: Amrita Mukherjee
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Expression of STAT3 and hypoxia markers in repeatedly resected glioma patients
Presenter: Katerina Dvorakova
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Unraveling the mechanisms of cisplatin resistance in bladder organoid by single cell RNA sequencing
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy
Presenter: Jelena Dinić
Session: Cocktail & Poster Display session
Resources:
Abstract
35P - Enhancing efficacy of the MEK inhibitor trametinib in KRAS-mutated colorectal cancer cells
Presenter: Lee Ellis
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Comparison of pelitinib, tepotinib or docetaxel efficacy according to the copy number or gene alteration status of EGFR, MET, HRAS, KRAS and NRAS genes
Presenter: Dae Young Zang
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - NET-mediated radio-resistance in early-stage non-small cell lung cancer
Presenter: Malcolm Ryan
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - The use of antibiotics or proton pump inhibitors and the response to intravesical Bacillus Calmette Guérin therapy in non-muscle-invasive bladder cancer
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - YAP1 promotes sorafenib resistance by activation of TGFβ signaling pathway
Presenter: Chit Lai Chee
Session: Cocktail & Poster Display session
Resources:
Abstract